This study aims to find out if a special cancer vaccine, used with a medicine called elranatamab, is safe and works well for people with relapsed or refractory multiple myeloma, a type of blood cancer. The vaccine is made from a patient's own cells to help their immune system fight cancer. This study lasts up to 5 years, including 12 cycles of treatment (each cycle is 28 days).
Key points to consider:
- Participants must be 18 or older with relapsed or refractory multiple myeloma.
- The study includes tests like blood and urine tests, scans, and clinic visits.
- Participants should not be on other experimental treatments or have certain health conditions.
Participants need to have stopped certain previous treatments and show no disease progression after initial therapy. Men and women of childbearing potential must use birth control during the study. This study involves regular medical check-ups and various tests to ensure safety and effectiveness.
How understandable was the trial content above?
Hard to understand
Easy to understand